Logo

ALBT

Avalon GloboCare Corp.

ALBT

Avalon GloboCare Corp. • NASDAQ
$1.47 ▼ -1.68% (-0.03)
Market Cap $5.62 M
52w High $11.66
52w Low $1.21
Dividend Yield 0%
P/E -0.17
Volume 72.42K
Outstanding Shares 3.84M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $350.099K ▼ $191.926K ▼ $-254.268K ▲ -72.627% ▲ $-0.06 ▲ $-163.467K ▲
Q2-2025 $350.406K ▲ $3.987M ▲ $-13.459M ▼ -3.841K% ▼ $-6.22 ▼ $-12.342M ▼
Q1-2025 $349.8K ▲ $1.876M ▲ $-2.482M ▲ -709.58% ▲ $-1.43 ▲ $-1.859M ▲
Q4-2024 $345.769K ▲ $1.385M ▲ $-2.725M ▼ -787.999% ▼ $-1.99 ▼ $-2.085M ▼
Q3-2024 $345.159K $1.37M $-1.679M -486.5% $-1.82 $-1.056M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $333.931K ▲ $9.128M ▲ $13.621M ▼ $-4.493M ▲
Q2-2025 $201.532K ▼ $7.988M ▼ $15.1M ▲ $-7.112M ▼
Q1-2025 $1.37M ▼ $10.61M ▼ $14.501M ▲ $-3.891M ▼
Q4-2024 $2.856M ▲ $20.985M ▲ $13.883M ▼ $7.103M ▲
Q3-2024 $1.024M $19.551M $14.149M $5.401M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-254.379K ▲ $-1.361M ▼ $657.635K ▲ $835.235K ▲ $132.399K ▲ $-1.361M ▼
Q2-2025 $-13.459M ▼ $-1.24M ▲ $-68.818K ▼ $128.279K ▼ $-1.168M ▲ $-1.24M ▲
Q1-2025 $-2.482M ▲ $-1.802M ▼ $95K ▼ $219.972K ▼ $-1.487M ▼ $-1.802M ▼
Q4-2024 $-2.725M ▼ $-1.093M ▲ $107.198K ▲ $2.822M ▲ $1.832M ▲ $-1.093M ▲
Q3-2024 $-1.679M $-1.639M $30.029K $2.428M $823.625K $-1.639M

Revenue by Products

Product Q3-2023Q4-2023Q1-2024
Corporate Other Member
Corporate Other Member
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Avalon GloboCare is effectively a pre-revenue company. It has not generated meaningful sales for several years, while continuing to record operating and net losses. The losses themselves are relatively small in absolute terms but consistent, which reflects a business still in development mode rather than one with an established commercial engine. Earnings per share have moved deeper into negative territory, partly influenced by share structure changes, and overall the income statement tells the story of a company investing in ideas without yet converting them into ongoing revenue.

Balance Sheet

Balance Sheet The balance sheet is very small and quite thin. Total assets are limited, with essentially no reported cash cushion and only modest tangible resources. Debt, while not large in absolute terms, has started to appear, and equity is also minimal. This suggests limited financial flexibility and a need to rely on external funding to support operations. The company does not currently have the kind of robust asset base or cash reserves that would provide a long safety runway if progress is slow or the strategic transition takes longer than expected.

Cash Flow

Cash Flow Cash flows mirror the income statement: money is steadily flowing out to cover operating expenses, with nothing meaningful coming in from customers. Operating and free cash flow have been negative over multiple years, and there is no visible investment in major physical assets, which is consistent with a small, research- and technology-oriented company. In practice, this means the business depends on raising capital from investors or lenders to keep funding its strategy until any of its technologies or new AI offerings begin to generate real cash.

Competitive Edge

Competitive Edge Avalon’s competitive position is unusual and in flux. Historically, it competed as a tiny player in very crowded, high-barrier biotech and diagnostics markets, where much larger pharmaceutical and medical device companies dominate. Its strengths have been specialized intellectual property, ties to reputable research institutions, and early moves into niche areas like breath-based diagnostics. Now, with the proposed shift toward AI-as-a-service through the YOOV merger, it is aiming at yet another intensely competitive space, this time full of established software and AI firms. The company’s small scale and limited resources are clear constraints, so its edge will likely depend on how well it can leverage its partnerships, patents, and any differentiated AI solutions rather than on financial muscle.

Innovation and R&D

Innovation and R&D Innovation is the core of Avalon’s story. On the biotech side, it has worked on advanced cell therapies, including CAR-T and CAR-NK technologies, and co-developed a protein design platform with a leading university, indicating access to high-end scientific capabilities. In diagnostics, it has focused on non-invasive breath-based devices, like its KetoAir product and a planned cannabis breathalyzer, which are differentiated and aimed at specific, emerging use cases. The potential merger with YOOV adds another innovation angle in AI automation, opening the door to combining life science know-how with AI tools, although the company has not fully spelled out how – or even whether – these domains will be integrated. Overall, there is no shortage of ideas and intellectual property, but most of this remains at an early or unproven commercial stage, so execution risk is high.

Summary

Avalon GloboCare is a very small, development-stage company undergoing a major strategic pivot. Financially, it has no meaningful revenue, ongoing but modest losses, and a thin balance sheet with limited cash, indicating dependence on external financing. Operationally, it is moving from biotech and diagnostics toward AI automation through a proposed merger, which could radically change its business profile. Its main assets are its patents, research collaborations, and niche diagnostic technologies, while its main challenges are scale, funding, and competing in industries dominated by much larger and better-capitalized players. The company’s future will largely hinge on whether it can successfully complete and integrate the AI-focused merger and bring any of its innovative technologies to commercial scale before its financial resources become too constrained.